banner
 
bar

program

  test
bar
 
 

Prevention & Management of
Venous Thromboembolism

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

The educational activity is designed for physicians likely to encounter patients at risk for VTE, among them: primary care physicians, hospitalist physicians, critical care specialists/intensivists, orthopedic surgeons, general surgeons, hematologists, pulmonologists, thrombosis medicine anticoagulation specialists, hospital-focused internists, surgical oncologists, and emergency medicine specialists.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

rocheSupported by an
independent educational grant
from Eisai, Inc.

Designation of Credit:

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS). The UMMS is accredited by ACCME to provide continuing medical education for physicians.
The UMMS designates this continuing medical education activity for up to 3 credit hours in Category 1 toward the Physicians Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Statement of Disclosure:

In accordance with the Standards of the Accreditation Council for Continuing Medical Education (ACCME) and the guidelines of the Association of American Medical Colleges (AAMC), it is the policy of the University of Massachusetts Medical School to disclose whatever interest or affiliation a speaker might have with any commercial organization whose products or services are related to the subject matter being presented.

Faculty Disclosures:

Samuel Z. Goldhaber, MD
Grant/Research Support: sanofi-aventis, Astra-Zeneca, GSK, Eisai, Mitsubishi
Consultant: sanofi-aventis, Bayer, BMS, Boehringer-Ingelheim

Russell Hull, MBBS, MSc
Grant/Research Support: sanofi-aventis, Bayer
Consultant: sanofi-aventis, Bayer, Wyeth, GSK

Craig M. Kessler, MD
Grant/Research Support: sanofi-aventis, Pfizer, GSK
Consultant: sanofi-aventis, GSK
Speaker's Bureau: sanofi-aventis, GSK

Program Faculty:

Samuel Z. Goldhaber, MD
Program Chairman and Series Medical Director
Professor of Medicine, Cardiovascular Division
Harvard Medical School
Director, Venous Thramboembolism
Research Group
Director, Anticoagulation Service
Brigham and Women's Hospital
Boston, MA

Russell Hull, MBBS, MSc
Professor of Medicine
Director, Thrombosis Research Unit
University of Calgary
Calgary, Alberta Canada

Craig M. Kessler, MD

Professor of Medicine and Pathology
Georgetown University Medical Center
Chief of the Division of Hematology-Oncology
Director of the Division of Coagulation
Department of Laboratory Medicine
Washington, DC

Educational Objectives:

  • Clinicians will learn how to apply current guidelines
    issued by national professional organizations and
    colleges, such as the ACCP, mandating risk-directed
    prophylaxis against DVT in at risk patients with medical
    and surgical conditions.
  • Clinicians will learn to risk stratify medical and surgical
    patients, assess their liklihood for incurring DVT, and be
    aware of prophylaxis measures that can reduce the incidence
    of DVT in the patient populations.
  • Clinicians will learn to assess and manage special needs
    of cancer patients at risk for DVT, with a focus on protecting
    against recurrent DVT.
  • Clinicians will learn to risk stratify patients undergoing
    general and orthopedic surgery, and implement ACCP-mandated
    pharmacologic and non-pharmacologic measures aimed at DVT
    prophylaxis.
  • Clinicians will learn how to apply landmark clinical
    trials focusing on DVT prevention in medical and surgical
    patients to their clinical practice.
  • Clinicians will learn how to evaluate, select among, and
    appropriately use the range of pharmacologic options available
    for DVT prophylaxis, including warfarin, unfractionated heparin,
    and LMWHs.

Disclaimer:

Copyright © 2006 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

  test
bar

YES, I have read the CME information statement

Copyright (c) 2007 All rights reserved


 
6

 

Key Program Topics Include:

ACCP Consensus Guidelines
Activation
Acute Illness
adhesive interactions
Akt
Angiogenesis
anticoagulants
Antithrombotic Therapy: Choices
ARISTOS
Armand Trousseau
ARTEMIS
Basement matrix
Bladder
Bleeding
Blood Coagulation
Brain
Breast
Cancer
Cancer Surgery
CANTHENOX
Central Venous Catheters
Cervix
Chemotherapy
CLOT
Clotting
Clotting dependent
Clotting independent
Coagulation
Colon
Dalteparin
Direct anti-IIa


Direct anti-Xa inhibitors
Distant
DVT
Eisai
Elastic Stockings
Endothelial
Endothelial cells
ENOXACAN
Enoxaparin
Esophagus
ETHICS
FAME
FIBRIN
Fibrinolytic
FRONTLINE
FVII/FVIIa
Gastrointestinal
Glioblastoma
Hematological
HIT
Hospitalization
Hypercoagulability
Hypoxia
IL-1
IL-8
immobilization
Inferior Vena Cava Filter
Kidney
Leukemia
Liver
LMWH
Low Molecular Weight

Heparin
Lung
Lymphoma
Malignancy
MALT
MEDENOX
medical illness (22%)
MET
metastases
Monocyte
Myeloma
Myeloprol
Nadroparin
ONCENOX
oncogene
Oncology
Ovary
PAI-1
PAI-2
Pancreas
PAR-2
Pathogenesis
Pentasaccharide
Platelets
PMN leukocyte
Pneumatic Compression
PREVENT
Procoagulant Activities
Prophylaxis
Prostate
Protease
Pseudopalisading

Pten
Radiotherapy
Ras
Rectal
SCLC
selectin/integrin-mediated
solid tumour malignancy
Stasis
Stomach
Surgery
TF
TF si mRNA
thrombohemorrhagic syndrome
thromboprophylaxis.
Thrombosis
Tinzaparin
TNF-α,
t-PA
Tumor cells
u-PA
u-PAR
Uterus
Vascular Injury
VEGF
VEGF
Venous thromboembolism
Virchow’s Triad
VTE
VTE in Hospitalized Cancer
Warfarin